https://pharmaphorum.com/ en Fri, 14 Nov 2025 14:31:41 +0000 Fri, 14 Nov 2025 14:30:31 +0000 https://pharmaphorum.com/news/sanofis-type-1-diabetes-drug-poised-eu-rollout Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes. Phil.Taylor https://pharmaphorum.com/news/sanofis-type-1-diabetes-drug-poised-eu-rollout 2025-11-14T14:30:31+0000 Feed - News and features https://pharmaphorum.com/news/lundbeck-makes-bid-avadel-trying-displace-alkermes Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product. Phil.Taylor https://pharmaphorum.com/news/lundbeck-makes-bid-avadel-trying-displace-alkermes 2025-11-14T13:33:44+0000 Feed - News and features https://pharmaphorum.com/news/kura-scores-fda-okay-rival-syndaxs-leukaemia-drug Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj. Phil.Taylor https://pharmaphorum.com/news/kura-scores-fda-okay-rival-syndaxs-leukaemia-drug 2025-11-14T12:00:47+0000 Feed - News and features https://pharmaphorum.com/news/medicxi-raises-eu500m-latest-biotech-fund Medicxi closes its fifth round, raising €500m for 'asset-centric' firms at all stages of development and taking the total raised in 10 years to €2bn+. Phil.Taylor https://pharmaphorum.com/news/medicxi-raises-eu500m-latest-biotech-fund 2025-11-14T10:51:23+0000 Feed - News and features https://pharmaphorum.com/news/update-msds-92bn-deal-flu-biotech-cidara-confirmed MSD has signed a $9.2 billion takeover deal for Cidara that will bolt on a universal flu prevention candidate in phase 3. Phil.Taylor https://pharmaphorum.com/news/update-msds-92bn-deal-flu-biotech-cidara-confirmed 2025-11-14T09:29:59+0000 Feed - News and features